Clinical Trial Agreement Considerations for Pharmaceutical Sponsors

Dive into this practice note for insightful guidance on negotiating and drafting clinical trial agreements (CTAs) on behalf of pharmaceutical companies. Pharmaceutical companies, commonly referred to as sponsors in the clinical trial context, often underestimate the importance of spending appropriate time and resources on CTAs. This practice note focuses on key CTA provisions that, if overlooked, can be very costly for organizations.

Read now »

Related Content

• Contract Research Organization Agreements
  Review this practice note to learn about negotiating and drafting agreements between a drug company or medical device company (a sponsor) and a contract research organization to design, monitor, or audit clinical trials.

• Clinical Research State Law Survey
  Use this state law survey to identify state laws and regulations on clinical trials, with a focus on payment and reimbursement, clinical trial populations, access to investigational treatments, and informed consent and confidentiality.

• Master Clinical Trial Agreement
  Start with this template to draft a clinical trial agreement between a drug or medical device manufacturer (sponsor) and an institution taking on responsibility for conducting a clinical trial on behalf of the sponsor. 

Practical Guidance Updates
Featuring the latest updates from your Practical Guidance account.   

• Listen up! Access our growing collection of podcasts by navigating to the Practical Guidance Podcasts Resource Kit. 
• The Practical Guidance Journal Fall Edition features impacts of the Dobbs v. Jackson Health Organization decision on employers, healthcare, insurance, and privacy concerns, and tracks the status of state law changes.
• Document alerts allow you to stay current on legal developments that affect your practice. Find out how to set up your document alerts. 

Experience results today with practical guidance, legal research, and data-driven insights—all in one place.

Experience Lexis+